Ashwell S G, Gebbie J, Home P D
University of Newcastle upon Tyne, Newcastle upon Tyne, UK.
Diabet Med. 2006 Jan;23(1):46-52. doi: 10.1111/j.1464-5491.2005.01726.x.
To compare blood glucose control when insulin glargine is given at lunch-time, dinner-time, and bed-time in people with Type 1 diabetes using insulin lispro at meal-times.
In this 16-week, three-way, cross-over study, 23 people with Type 1 diabetes were randomized to insulin glargine injection at lunch-time (L) [mean 12.37 +/- 00.34 (+/- sd) h], dinner-time (D) (18.12 +/- 00.40 h), or bed-time (B) (22.29 +/- 00.40 h), each plus meal-time insulin lispro. Each 4-week treatment period concluded with a 24-h inpatient metabolic profile.
Insulin doses, HbA(1c), and fructosamine concentration did not differ between treatment periods. Pre-breakfast self-monitored blood glucose (SMBG) concentration was higher with injection of glargine at lunch-time than at other times [L: 9.2 +/- 0.3 (+/- se) vs. D: 8.2 +/- 0.3 or B: 8.0 +/- 0.3 mmol/l, P = 0.016], as probably was pre-lunch SMBG (L: 8.6 +/- 0.7 vs. D: 6.4 +/- 0.7 or B: 6.4 +/- 0.8 mmol/l, P = 0.051). Pre-dinner SMBG level was higher with dinner-time glargine than other injection times (D: 9.4 +/- 0.9 vs. L: 4.9 +/- 0.9 or B: 7.4 +/- 1.1 mmol/l, P = 0.007). For 22.00 to 02.00 h, mean inpatient plasma glucose concentration was higher with injection of glargine at bed-time than other times (B: 9.1 +/- 0.6 vs. L: 7.8 +/- 0.6 or D: 6.7 +/- 0.6 mmol/l, P = 0.023). Plasma free insulin concentration was lower at the end of the afternoon with dinner-time glargine than other injection times (D: 11.5 +/- 1.4 vs. L: 20.2 +/- 1.3 or B: 16.5 +/- 1.3 mU/l, P < 0.001). Frequency of hypoglycaemia was not different, but timing of hypoglycaemia differed between treatment periods.
Blood glucose levels rise around the time of injection of insulin glargine whether given at lunch-time, dinner-time or bed-time. Bed-time injection leads to hyperglycaemia in the early part of the night which is improved by giving insulin glargine at lunch-time or dinner-time.
比较1型糖尿病患者在餐时使用赖脯胰岛素的情况下,甘精胰岛素分别在午餐时、晚餐时和睡前注射时的血糖控制情况。
在这项为期16周的三向交叉研究中,23名1型糖尿病患者被随机分为在午餐时(L)[平均12.37±00.34(±标准差)小时]、晚餐时(D)(18.12±00.40小时)或睡前(B)(22.29±00.40小时)注射甘精胰岛素,每种情况均加用餐时赖脯胰岛素。每个为期4周的治疗期结束时进行一次24小时住院代谢评估。
各治疗期之间的胰岛素剂量、糖化血红蛋白(HbA₁c)和果糖胺浓度无差异。早餐前自我监测血糖(SMBG)浓度在午餐时注射甘精胰岛素时高于其他时间[L:9.2±0.3(±标准误)与D:8.2±0.3或B:8.0±0.3 mmol/L,P = 0.(此处可能有误,原文0.016)],午餐前SMBG可能也是如此(L:8.6±0.7与D:6.4±0.7或B:6.4±0.8 mmol/L,P = 0.051)。晚餐前SMBG水平在晚餐时注射甘精胰岛素时高于其他注射时间(D:9.4±0.9与L:4.9±0.9或B:7.4±1.1 mmol/L,P = 0.007)。在22:00至02:00期间,住院患者血浆葡萄糖平均浓度在睡前注射甘精胰岛素时高于其他时间(B:9.1±0.6与L:7.8±0.6或D:6.7±0.6 mmol/L,P = 0.023)。下午结束时,晚餐时注射甘精胰岛素时的血浆游离胰岛素浓度低于其他注射时间(D:11.5±1.4与L:20.2±1.3或B:16.5±1.3 mU/L,P < 0.001)。低血糖发生频率无差异,但各治疗期低血糖发生时间不同。
无论甘精胰岛素在午餐时、晚餐时还是睡前注射,注射时周围血糖水平都会升高。睡前注射会导致夜间早期出现高血糖,而在午餐时或晚餐时注射甘精胰岛素可改善这种情况。